News from partner therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 15, 2022, 13:47 ET Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal Therapy

Partner Therapeutics, Inc. (PTx) announced publication of a single institution retrospective cohort review of 15 patients with pediatric malignancies ...

Mar 29, 2022, 15:30 ET Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of results from investigator-sponsored pre-clinical research...

Feb 17, 2022, 07:30 ET Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure

Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense...

Sep 20, 2021, 08:45 ET BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients

Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the...

Aug 17, 2021, 14:01 ET "A Drug Before Its Time?" LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity

Partner Therapeutics, Inc. (PTx) announced today that Frontiers in Immunology published a systematic review of LEUKINE® titled, "Sargramostim (rhu...

Jun 28, 2021, 03:00 ET Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function

Partner Therapeutics, Inc. (PTx) announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine (sargramostim,...

May 19, 2021, 12:16 ET Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson's Disease

artner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial...

Apr 29, 2021, 08:40 ET Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE clinical...

Mar 24, 2021, 07:05 ET Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial...

Mar 03, 2021, 09:32 ET Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics...

Feb 26, 2021, 03:05 ET SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function

Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic...

Feb 18, 2021, 07:30 ET Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of...

Sep 15, 2020, 08:00 ET Partner Therapeutics (PTx) Announces the Appointment of Ed Rock as Chief Medical Officer

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock, MD, PhD to serve as the...

Sep 11, 2020, 07:30 ET Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI)...

Aug 25, 2020, 07:58 ET Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm...

Aug 04, 2020, 08:00 ET Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, today anounced a $35 million milestone-based Other Transaction Agreement (OTA)...

Jun 11, 2020, 08:00 ET Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated...

May 28, 2020, 14:30 ET Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind,...

Mar 24, 2020, 10:33 ET Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness

Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients...

Nov 07, 2019, 08:00 ET Partner Therapeutics (PTx) Announces the Appointment of John McManus as Chief Business Officer

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that it appointed John McManus to serve as the company's Chief...

Sep 19, 2019, 07:45 ET Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim)

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

Nov 06, 2018, 07:54 ET Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

Jun 06, 2018, 07:54 ET Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome

Commercial-stage cancer biotech company, Partner Therapeutics, Inc. (PTx), announced the recent FDA approval of Leukine for the treatment of adult...

Mar 07, 2018, 07:54 ET Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today the appointment of Ellen Hukkelhoven and Terry Gould to the company's...

Feb 01, 2018, 06:56 ET Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it has acquired the global rights to develop, manufacture, and...